Who is eligible for clinical trial NCT06959225?

Participants must meet the protocol's inclusion criteria for Hidradenitis Suppurativa. The stated age range is 12 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06959225 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-24

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) (NCT06959225)

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Incyte Corporation

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (7 items).

Location: Investigative Site US020 — Phoenix, Arizona

Age range: 12 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Diagnosis of HS for at least 6 months prior to screening visit.
Mild to moderate HS (Hurley I or II) with the following at both screening and baseline visits:
A total AN count of at least 4, with no draining tunnels AND
Affecting at least 2 distinct anatomical areas
Agreement to NOT use topical and systemic antibiotics for treatment of HS during the vehicle-controlled period.
Agreement to NOT use topical antiseptics, including washes and leave-on products on the areas affected by HS lesions during the vehicle-controlled period and Weeks 16 to 20 of the extension period.
Further inclusion criteria apply.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Body surface areas to be treated exceed 20% BSA at screening or baseline
Presence of draining tunnels at screening or baseline.
Medical history including current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
Laboratory values outside of the protocol-defined criteria.
Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.
Further exclusion criteria apply.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (101 Sites)

Showing the first 25 of 101 sites.

Investigative Site US020 — Phoenix, Arizona
Investigative Site US033 — Scottsdale, Arizona
Investigative Site US054 — Tempe, Arizona
Investigative Site US002 — Fayetteville, Arkansas
Investigative Site US055 — Brea, California
Investigative Site US004 — Laguna Niguel, California
Investigative Site US007 — Los Angeles, California
Investigative Site US013 — San Diego, California
Investigative Site US060 — San Diego, California
Investigative Site US038 — San Diego, California
Investigative Site US059 — Aurora, Colorado
Investigative Site US045 — Boynton Beach, Florida
Investigative Site US028 — Fort Myers, Florida
Investigative Site US016 — Miami, Florida
Investigative Site US027 — Sanford, Florida
Investigative Site US057 — Sweetwater, Florida
Investigative Site US029 — Tampa, Florida
Investigative Site US061 — Atlanta, Georgia
Investigative Site US053 — Atlanta, Georgia
Investigative Site US019 — Marietta, Georgia
Investigative Site US026 — Chicago, Illinois
Investigative Site US049 — Clarksville, Indiana
Investigative Site US052 — West Lafayette, Indiana
Investigative Site US001 — Bowling Green, Kentucky
Investigative Site US022 — Louisville, Kentucky

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hidradenitis Suppurativa

Real-world Secukinumab Outcomes in Canadian HS Patients — Calgary, Alberta
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. — Phoenix, Arizona
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa — Phoenix, Arizona
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy — Phoenix, Arizona
Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa. — Birmingham, Alabama
Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository — San Francisco, California

Explore by condition: All Hidradenitis Suppurativa clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗